Celentyx offers bespoke Human Immuno-Profiling opportunities to partners in strategic alliance with leading international expertise in immune cell subtypes and associated pathologies within the MRC Centre for Immune Regulation at Birmingham, U.K. to mine Mechanisms of Action and disclose novel applications for new and reprofiled drugs/compounds. Predictive immuno-toxicology (unwanted reactions) can also be profiled. Specialities (compound versus human cell subsets) include assay, enumeration, and function of: Tregs; TH17; TH1/TH2; NK & NKT; Bregs; naive versus memory B cells; B1 cells; monocytes/macrophages; DCs; haematological malignancies. More recently, Celentyx has developed a suite of sophisticated platforms for evaluating novel and established biologics in the burgeoning ImmunoOncology space.
University of Birmingham
School of Immunity & Infection
As well as being an international force in his chosen research field of Human B-cell Biology & Pathophysiology, John has been a senior figure in the administration of the College of Medical & Dental Sciences at Birmingham holding a number of posts including that of Head of Graduate School and Associate Director of Research & Knowledge Transfer. He retired and earned Professor Emeritus status in July 2013.